Comparative Pharmacology
Head-to-head clinical analysis: OVCON 35 versus TRI LEGEST FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OVCON 35 versus TRI LEGEST FE.
OVCON-35 vs TRI-LEGEST FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity, impeding sperm penetration.
Tri-Legest FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It prevents ovulation by inhibiting gonadotropin release (FSH and LH) and alters cervical mucus and endometrial lining to impede sperm penetration and implantation.
One tablet (35 mcg ethinyl estradiol and 0.4 mg norethindrone) orally once daily.
One tablet orally once daily for 28-day cycle: 21 days active tablets (norethindrone/ethinyl estradiol) followed by 7 days placebo. For contraception only.
None Documented
None Documented
Ethinyl estradiol: 5-18 hours (mean ~12 hours, biphasic); norethindrone: 5-14 hours (mean ~8 hours). Terminal half-life relevant for once-daily dosing.
Norethindrone: 7-8 hours; Ethinyl estradiol: 18 hours (terminal). Steady-state reached after 7 days; clinical contraceptive efficacy requires consistent dosing.
Renal 60% (metabolites, glucuronide conjugates), fecal 10%, biliary 5%, remainder via other pathways.
Renal: ~60% (metabolites), Fecal: ~30% (metabolites), Biliary: minor (~5% as conjugates)
Category C
Category C
Oral Contraceptive
Oral Contraceptive